Similar articles for PMID: 26338895

Year	Number of Results
1991	1
1996	1
1997	1
1998	1
1999	3
2001	4
2003	2
2004	2
2006	8
2007	4
2008	3
2009	5
2010	7
2011	6
2012	6
2013	12
2014	8
2015	8
2016	8
2017	12
2018	9
2019	11
2020	9
2021	11
2022	2
2024	0

1

Time Evolution of DOTATOC Uptake in Neuroendocrine Tumors in View of a Possible Application of Radioguided Surgery with β- Decay.

Collamati F, Bellini F, Bocci V, De Lucia E, Ferri V, Fioroni F, Grassi E, Iori M, Marafini M, Morganti S, Paramatti R, Patera V, Recchia L, Russomando A, Sarti A, Sciubba A, Senzacqua M, Solfaroli Camillocci E, Versari A, Voena C, Faccini R. Collamati F, et al. J Nucl Med. 2015 Oct;56(10):1501-6. doi: 10.2967/jnumed.115.160481. Epub 2015 Sep 3. J Nucl Med. 2015. PMID: 26338895 Free article.

2

Toward radioguided surgery with β- decays: uptake of a somatostatin analogue, DOTATOC, in meningioma and high-grade glioma.

Collamati F, Pepe A, Bellini F, Bocci V, Chiodi G, Cremonesi M, De Lucia E, Ferrari ME, Frallicciardi PM, Grana CM, Marafini M, Mattei I, Morganti S, Patera V, Piersanti L, Recchia L, Russomando A, Sarti A, Sciubba A, Senzacqua M, Solfaroli Camillocci E, Voena C, Pinci D, Faccini R. Collamati F, et al. J Nucl Med. 2015 Jan;56(1):3-8. doi: 10.2967/jnumed.114.145995. Epub 2014 Dec 11. J Nucl Med. 2015. PMID: 25500828 Free article.

3

First Ex Vivo Results of β^--Radioguided Surgery in Small Intestine Neuroendocrine Tumors with ⁹⁰Y-DOTATOC.

Bertani E, Collamati F, Colandrea M, Faccini R, Fazio N, Ferrari ME, Fischetti M, Fumagalli Romario U, Funicelli L, De Simoni M, Mancini-Terracciano C, Mirabelli R, Morganti S, Papi S, Pisa E, Solfaroli-Camillocci E, Spada F, Cremonesi M, Grana CM. Bertani E, et al. Cancer Biother Radiopharm. 2021 Jun;36(5):397-406. doi: 10.1089/cbr.2020.4487. Epub 2021 Feb 18. Cancer Biother Radiopharm. 2021. PMID: 33601932

4

Radioguided surgery with β^- radiation in pancreatic Neuroendocrine Tumors: a feasibility study.

Collamati F, Maccora D, Alfieri S, Bocci V, Cartoni A, Collarino A, Simoni M, Fischetti M, Fratoddi I, Giordano A, Mancini-Terracciano C, Mirabelli R, Morganti S, Quero G, Rotili D, Scotognella T, Solfaroli Camillocci E, Traini G, Venditti I, Faccini R. Collamati F, et al. Sci Rep. 2020 Mar 4;10(1):4015. doi: 10.1038/s41598-020-61075-2. Sci Rep. 2020. PMID: 32132632 Free PMC article. Clinical Trial.

5

Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.

Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U. Kowalski J, et al. Mol Imaging Biol. 2003 Jan-Feb;5(1):42-8. doi: 10.1016/s1536-1632(03)00038-6. Mol Imaging Biol. 2003. PMID: 14499161

6

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.

Kwekkeboom DJ, Kooij PP, Bakker WH, Mäcke HR, Krenning EP. Kwekkeboom DJ, et al. J Nucl Med. 1999 May;40(5):762-7. J Nucl Med. 1999. PMID: 10319747 Free article.

7

Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.

Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B. Velikyan I, et al. J Nucl Med. 2014 Feb;55(2):204-10. doi: 10.2967/jnumed.113.126177. Epub 2013 Dec 30. J Nucl Med. 2014. PMID: 24379222 Free article. Clinical Trial.

8

Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent ¹⁷⁷Lu-DOTATOC therapy.

Goetz TI, Lang EW, Prante O, Maier A, Cordes M, Kuwert T, Ritt P, Schmidkonz C. Goetz TI, et al. Ann Nucl Med. 2020 Apr;34(4):244-253. doi: 10.1007/s12149-020-01440-3. Epub 2020 Feb 29. Ann Nucl Med. 2020. PMID: 32114682 Free PMC article.

9

Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of ⁶⁸Ga DOTATOC as Assessed by Dynamic Whole-body PET in Patients with Neuroendocrine Tumors: Implications for Diagnosis and Therapy.

Lodge MA, Solnes LB, Chaudhry MA, Wahl RL. Lodge MA, et al. Mol Imaging Biol. 2021 Oct;23(5):766-774. doi: 10.1007/s11307-021-01600-5. Epub 2021 Apr 7. Mol Imaging Biol. 2021. PMID: 33829361

10

Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.

Todorović-Tirnanić M, Kaemmerer D, Prasad V, Hommann M, Baum RP. Todorović-Tirnanić M, et al. Recent Results Cancer Res. 2013;194:487-96. doi: 10.1007/978-3-642-27994-2_28. Recent Results Cancer Res. 2013. PMID: 22918778

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

127 results

Results by year